PageOverview.com
 

Domains targeting keyword vaccines events

Keyword vaccines events was used in the provided list of websites.

 
Number of websites/domains displayed: 9
Results found: 9
 

Similar searches:

 

Websites discovered:

Vaccine Injury Compensation Canada - Vaccine Injury Compensation Canada
http://pageoverview.com/website-report/vaccineinjurycompensationcanada.weebly.com
Canada does not have a vaccine injury compensation program, but badly needs one. This website is a source of infomation for those who suffered a vaccine injury.
  • Google Analytics: 7870337-1
MICE Industry, Events & Travel | Market Width
http://pageoverview.com/website-report/market-width.com
MICE Industry, Events and Travel - Market Width offers list of MICE Events; Event venues; MICE & Travel industries Blogs and news; & list of International Associations.
  • Expected expiration: February 28th in 2019
  • Creation date: February 28th in 2014
  • Renew date: January 29th in 2018
  • Adsense ID: pub-4120836660914347
  • Google Analytics: 49391168-1
  • Google Plus Account: +Market-Width
Merck Newsroom Home
http://pageoverview.com/website-report/mrknewsroom.com
Merck's online newsroom allows journalists, consumers and investors to find real-time news about Merck's prescription medicines, vaccines and consumer care products.
  • Expected expiration: February 7th in 2018
  • Creation date: February 7th in 2017
  • Renew date: February 7th in 2017
  • Google Analytics: 23746697-21
Meetings International Pte Ltd | International Conferences | Asia | Australia | Middle East | USA| Europe | UK | Canada | Pharma | Healthcare | Biotech | Medical | Clinical | Engineering | 2017 | 2018
http://pageoverview.com/website-report/meetingsint.com
Meetings International pte ltd offers world class conferences and exhibitions in various fields like pharma, medical, clinical, healthcare, and engineering at various destinations like india, china, australia, dubai, Singapore, malaysia, Indonesia, Thailand, south korea, new zealand and taiwan. It also provides global networking opportunities to all the attendees
  • Expected expiration: May 27th in 2018
  • Creation date: May 27th in 2015
  • Renew date: November 1st in 2016
  • Google Plus Account: 110182556395678225793
  • Google Analytics: 112094404-1
  • AddThis User: ra-51c0a69a54129237
Vaccines Conferences 2018 | Immunization Meetings | Vaccines B2B Expos | USA | Europe | Asia-Pacific | Middle East
http://pageoverview.com/website-report/vaccineconferences.com
Conferenceseries.com organizing Vaccines Conferences in USA, Europe, Australia and other prominent locations across the globe. We organise Vaccines meetings in the fields related to Vaccines like Immunology, Clinical Trails and Cell Research.
  • Expected expiration: February 11th in 2018
  • Creation date: February 11th in 2016
  • Renew date: January 19th in 2017
  • Google Plus Account: +Omicsgroup
  • Google Analytics: 54523462-1
  • AddThis User: ra-51c0a69a54129237
Inducing Remission in GPA & MPA Patients | Rituxan® GPA & MPA | HCP
http://pageoverview.com/website-report/rituxanforgpampa-hcp.com
Find information for healthcare professionals about Rituxan® (rituximab), the only FDA-approved treatment proven to induce remission in patients with GPA and MPA. INDICATION STATEMENT - Rituxan® (rituximab), in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) - Limitations of Use: Rituxan is not recommended for use in patients with severe, active infections BOXED WARNINGS and Additional Important Safety Information BOXED WARNINGS Infusion Reactions: Rituxan administration can result in serious, including fatal, infusion reactions. Deaths within 24 hours of Rituxan infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Monitor patients closely. Discontinue Rituxan infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion reactions. Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving Rituxan. Hepatitis B Virus (HBV) Reactivation: HBV reactivation can occur in patients treated with Rituxan, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with Rituxan. Discontinue Rituxan and concomitant medications in the event of HBV reactivation. Progressive Multifocal Leukoencephalopathy (PML): PML, including fatal PML, can occur in patients receiving Rituxan. Warnings and Precautions Rituxan administration can also result in additional serious, including fatal, adverse reactions including: - Tumor lysis syndrome (TLS): Administer aggressive intravenous hydration, anti‑hyperuricemic agents, monitor renal function - Infections: Withhold Rituxan and institute appropriate anti-infective therapy - Cardiac arrhythmias and angina: Discontinue infusions in case of serious or life-threatening events - Bowel obstruction and perforation: Consider and evaluate for abdominal pain, vomiting, or related symptoms - Live virus vaccines: Do not administer live virus vaccines prior to or during Rituxan - Cytopenias: Monitor blood counts at regular intervals Granulomatosis With Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) - Use of concomitant immunosuppressants other than corticosteroids has not been studied in GPA or MPA patients exhibiting peripheral B-cell depletion following treatment with Rituxan. Observe patients with GPA and MPA closely for signs of infection if immunosuppressants other than corticosteroids are used concomitantly - The safety and efficacy of retreatment with Rituxan have not been established in patients with GPA and MPA - Common adverse reactions (≥15%) in the clinical study were infections, nausea, diarrhea, headache, muscle spasms, anemia, and peripheral edema. Other important adverse reactions include infusion reactions You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. For additional safety information, please see the Rituxan full prescribing information, including BOXED WARNINGS.
  • Expected expiration: November 27th in 2019
  • Creation date: November 27th in 2013
  • Renew date: December 1st in 2017
  • Google Analytics: 48974804-1
STFN Stranger Than Fiction News
http://pageoverview.com/website-report/stfnews.com
Truth Is Stranger Than Fiction
  • Expected expiration: August 21st in 2017
  • Creation date: August 21st in 2015
  • Renew date: August 22nd in 2016
Vaccinations; are your choice, make an informed one. ~ Vaccines, Health & Adverse Events,measles,Pertussis,
http://pageoverview.com/website-report/vaccination.co.uk
Vaccines, Health & Adverse Events,measles,Pertussis,
  • Renew date: February 21st in 2018
  • Google Analytics: 35365099-1
Merck Newsroom Home
http://pageoverview.com/website-report/mercknewsroom.com
Merck's online newsroom allows journalists, consumers and investors to find real-time news about Merck's prescription medicines, vaccines and consumer care products.
  • Expected expiration: September 27th in 2017
  • Creation date: September 27th in 2012
  • Renew date: July 21st in 2015
  • Google Analytics: 23746697-21
0.0133 // 2024-06-03 22:59:24
All Rights reserved 2018 © PageOverview.com